Synergistic and attenuated effect of HSS in combination treatment with docetaxel plus cisplatin in human non-small-cell lung SPC-A-1 tumor xenograft

Biomedicine and Pharmacotherapy

Volumn 79, Issue , 2016, Pages 27-34

  Jia, Yuping ^a   Zhou, Dongshun ^b   Jia, Qingwen ^a   Ying, Yong ^c   Chen, Shuntai ^c  

^a Shandong Academy of Pharmaceutical Science   (China)

^b SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG FIRST MEDICAL UNIVERSITY   (China)

^c Cancer Hospital of Qindao Haisheng Co Ltd   (China)

Author keywords

Additive effect; Antitumor activity; Cisplatin; Docetaxel; HSS; Toxicity

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CISPLATIN; DOCETAXEL; SODIUM CHLORIDE; ANTINEOPLASTIC AGENT; PLANT PROTEIN; TAXOID;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BIOCHEMICAL ANALYSIS; BODY WEIGHT; CANCER ADJUVANT THERAPY; CANCER INHIBITION; FOOD INTAKE; HUMAN; HUMAN CELL; IN VIVO STUDY; LEUKOCYTE; MALE; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTE COUNT; TUMOR GROWTH; TUMOR GROWTH INHIBITION RATE; TUMOR XENOGRAFT; UREA NITROGEN BLOOD LEVEL; ANIMAL; BLOOD; CARCINOMA, NON-SMALL-CELL LUNG; CELL PROLIFERATION; DRUG EFFECTS; DRUG POTENTIATION; DRUG SCREENING; FEEDING BEHAVIOR; LUNG NEOPLASMS; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BODY WEIGHT; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; DRUG SYNERGISM; FEEDING BEHAVIOR; HUMANS; LUNG NEOPLASMS; MICE, NUDE; PLANT PROTEINS; TAXOIDS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84961927057     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2016.01.043     Document Type: Article

References (37)

1. Govindan R., Page N., Morgensztern D., Read W., Tierney R., Vlahiotis A., Spitznagel E.L., Piccirillo J. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J. Clin. Oncol. 2006, 24:4539-4544. [PubMed: 17008692].
2. Bunn P.A. The expanding role of cisplatin in the treatment of non-small-cell lung cancer. Semin. Oncol. 1989, 6(4 Suppl. 6). [PubMed: 2548280].
3. Cerny T., Kaplan S., Pavlidis N., Schöffski P., Epelbaum R., van Meerbeek J., Wanders J., Franklin H.R., Kaye S. Docetaxel (Taxotere) is active in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group (ECTG). Br. J. Cancer 1994, 70:384-387. [PubMed: 7914429].
4. Le Chevalier T., Brisgand D., Soria J.C., Douillard J.Y., Pujol J.L., Ruffie P., Aberola V., Cigolari S.Long Termanalysis of survival in European randomized trial comparing vinorelbine/cisplatin to vindesine/cisplatin and vinorelbine alone in advanced non-small cell lung cancer. Oncologist 2001, 6(Suppl. 1):8-11. [PubMed: 11181998].
5. Bonomi P., Kim K., Fairclough D., Cella D., Kugler J., Rowinsky E., Jiroutek M., Johnson D. Comparison of survival and quality of life in advanced non-small cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J. Clin. Oncol. 2000, 18:361-623. [PubMed: 10653877].
6. Kubota K., Watanabe K., Kunitoh H., Noda K., Ichinose Y., Katakami N., et al. Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: the Japanese Taxotere Lung Cancer Study Group. J. Clin. Oncol. 2004, 22:254-261. [PubMed: 14722033].
7. Wakelee H., Belani C.P. Optimizing first-line treatment options for patients with advanced NSCLC. Oncologist 2005, 1-10. [PubMed: 16368866].
8. Douillard J.Y., Eckardt J., Scagliotti G.V. Challenging the platinum combinations in the chemotherapy of NSCLC. Lung Cancer 2002, 21-28. [PubMed: 12480191].
9. Jung W.K., Jo H.Y., Qian Z.J., Jeong Y.J., Park S.G., Choi I.W., et al. A novel anticoagulant protein with high affinity to blood coagulation factor Va from Tegillarca granosa. J. Biochem. Mol. Biol. 2007, 40:832-838. [PubMed: 17927919].
10. Lv S., Gao J., Liu T., Zhu J., Xu J., Song L., et al. Purification and partial characterization of a new antitumor protein from Tegillarca granosa. Mar. Drugs. 2015, 13:1466-1480. [PubMed: 25789603].
11. Xu W., Chang Z., Liu X., Jiang C., Wang C., Xu L. Antitumor effects of a polypeptide isolated from Tegillarca granosa linnaeus and the related molecular mechanism. Pak. J. Pharm. Sci. 2014, 27:565-570. [PubMed: 24811818].
12. Chen S.G. Marine-derived anticancer protein and its extraction method. Chin. Pat. 2006, No. CN1752100A.
13. Chen S.G., Liu X.R., Yang X., Wang C.B. Study on quality standards for Haishengsu injection. Chin. J. Mar. Drugs 2006, 25:43-46.
14. Han Z.W., Chu X., Guo S.B. HPLC fingerprint and quality control of Haishengsu lyophilized power isolated from Tegillarca granosa. Chin. J. Mar. Drugs 2005, 24:42-46.
15. Yao R.Y., Chu X., Zhang Y.J., et al. Anti-tumor effect of Haishengsu extracted from Tegillarca granosa in vitro and in vivo. Chin. J. Mar. Drugs 2005, 24:33-36.
16. Li G.Y., Yu X.M., Zhang H.W., Zhang B., Wang C.B., Xin Y.C., et al. Haishengsu as an adjunct therapy to conventional chemotherapy in patients with non-small cell lung cancer: a pilot randomized and placebo-controlled clinical trial. Complement. Ther. Med. 2009, 17:51-55. [PubMed: 19114229].
17. Geran R.I., Greenberg N.H., Mac Donald M.M., et al. Protocols for screening chemical agents and natural products against animal tumors and other biological systems. Cancer Chemother. Rep. 1972, 3:1-88.
18. Wu Y.D., Chen Y., Chen W.J. Effects of concurrent use of rh-IFN-γ on the antiproliferative capacity on HL-60 cells caused by curcumin. Cancer (Chin) 1999, 18:635-638. [PubMed: 12938514].
19. Non-small Cell Lung Cancer Collaborative Group Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995, 311:899-909. [PubMed: 7580546].
20. Spiro S.G., Rudd R.M., Souhami R.L., et al. Chemotherapy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of life. Thorax 2004, 59:828-836. [PubMed: 15454647].
21. D'Addario G., Pintilie M., Leighl N.B., Feld R., Cerny T., Shepherd F.A. Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. J. Clin. Oncol. 2005, 23:2926-2936. [PubMed: 15728229].
22. Sun H.B., Wang S.Y., Ou W., Zhang B.B., Yang H., Fang Q. The feasibility of adjuvant carboplatin and docetaxel in patients with curatively resected locally advanced non-small cell lung cancer. Lung Cancer 2010, 68:403-408. [PubMed: 19913325].
23. Liu J.Z., Yang M., Li D.P., Zhang B., Chen S.G., Wang C.B., Li G.Y., Wang L.X. Effect of Haishengsu on transplanted K562 and drug-resistant K562/ADM tumors: an experimental study. Clin. Invest. Med. 2009, 32(2):E117-E123. [PubMed: 19331800].
24. Xu W., Kong X., Jiang C., Liu X., Xu L. The anti-tumor effect of a polypeptide extracted from Tegillarca granosa Linnaeus on renal metastatic tumor OS-RC-2 cells. Arch. Med. Sci. 2015, 11(4):849-855. [PubMed: 263220971].
25. Gao M.Q., Han Y.T., Zhu L., Chen S.G., Hong Z.Y., Wang C.B. Cytotoxicity of natural extract from Tegillarca granosa on ovarian cancer cells is mediated by multiple molecules. Clin. Invest. Med. 2009, 32(5):E368-E375. [PubMed: 19796578].
26. Li G.Y., Liu J.Z., Yu X.M., Chen S.F., Zhang B., Zhang W.F., Xiao T.W., Wang C.B., Wang L.X. Effect of a seashell protein Haishengsu on cell growth and expression of apoptosis genes in leukemia K562 cells. Clin. Invest. Med. 2008, 31(4):E218-21. [PubMed: 18682046].
27. Li G.Y., Liu J.Z., Chen S.G., Zhang B., Wang C.B., Wang L.X. Tegillarca granosa extract Haishengsu inhibits the expression of P-glycoprotein and induces apoptosis in drug-resistant K562/ADM cells. Pharm. Biol. 2010, 48(5):529-533. [PubMed: 20645795].
28. Li G.Y., Liu J.Z., Zhang B., Yang M., Chen S.G., Hou M., Wang L.X. Tegillarca granosa extract Haishengsu (HSS) suppresses expression of mdr1, BCR/ABL and sorcin in drug-resistant K562/ADM tumors in mice. Adv. Med. Sci. 2013, 58(1):112-117. [PubMed: 23729583].
29. Chen X., Han Y., Zhan S., Wang C., Chen S. Tegillarca granosa extract Haishengsu induces apoptosis in human hepatocellular carcinoma cell line BEL-7402 via Fas-signaling pathways. Cell Biochem. Biophys. 2015, 71(2):837-844. [PubMed: 25257131].
30. Liu J.Z., Chen S.G., Bin Z., Wang C.B., Li G.Y., Wang L.X. Antitumor effect of the seashell protein Haishengsu on Ehrlich ascites tumor: an experimental study. J. Nat. Med. 2009, 63(4):459-462. [PubMed: 19536610].
31. Li G.Y., Liu J.Z., Chen S.G., Wang C.B., Bin Z., Wang L.X. Effect of a seashell protein Haishengsu on the immunological function of mice with Ehrlich ascites tumor. Immunopharmacol. Immunotoxicol. 2009, 31(4):669-674. [PubMed: 19874239].
32. Liu J.Z., Chen S.G., Zhang B., Wang C.B., Zhao X.W., Li G.Y., Wang L.X. Effect of haishengsu as an adjunct therapy for patients with advanced renal cell cancer: a randomized and placebo-controlled clinical trial. J. Altern. Complement Med. 2009, 15(10):1127-1130. [PubMed: 19821717].
33. Rahman M.F., Siddiqui M.K., Jamil K. Effects of Vepacide (Azadirachta indica) on aspartate and alanine aminotransferase profiles in a subchronic study with rats. Hum. Exp. Toxicol. 2001, 20:243-249. [PubMed: 11476156].
34. Ramaiah S.K. A toxicologist guide to the diagnostic interpretation of hepatic biochemical parameters. Food Chem. Toxicol. 2007, 45:1551-1557. [PubMed: 17658209].
35. Han Y.D., Song S.Y., Lee J.H., Lee D.S., Yoon H.C. Multienzyme-modified biosensing surface for the electrochemical analysis of aspartate transaminase and alanine transaminase in human plasma. Anal Bioanal. Chem. 2011, 400:797-805. [PubMed: 21359826].
36. Pratt D.S., Kaplan M.M. Evaluation of abnormal liver-enzyme results in asymptomatic patients. N. Engl. J. Med. 2000, 342:1266-1271. [PubMed: 10781624].
37. Ozer J., Ratner M., Shaw M., Bailey W., Schomaker S. The current state of serum biomarkers of hepatotoxicity. Toxicology 2008, 245:194-205. [PubMed: 18291570].